GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2019 Epidiolex U.S. Q2 net sales of $68.4 million Positive CHMP opinion clears way for an expected European approval in October Conference call today at 4:30 p.m. EST CARLSBAD, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc
[Read More ...]
from
https://www.newcannabisventures.com/epidiolex-sales-drive-gw-pharmas-68-million-revenue-in-q2/
No comments:
Post a Comment